Content of review 1, reviewed on February 22, 2022

This manuscript describes an off-medication follow up of the STEP 1 phase 3 trial of semaglutide.

The rebound in weight, and the loss of benefit is as expected once active treatment is discontinued.

One finding I found somewhat surprising was that there appeared to be no difference between the entire cohort and the cohort once the subjects who received some type of pharmacotherapy were removed(Fig 1 panels A and C) ?

It may be of interest to report the weight maintenance in the 21 subjects in the semaglutide arm and 6 subjects in the placebo arm who received some type of pharmacotherapy but no behavioral intervention.

The STEP 4 trial has clearly shown that continued pharmacotherapy with behavioral intervention continues to be effective.

Source

    © 2022 the Reviewer.

Reviewed on April , 2022
Source

    © 2022 the Reviewer.

References

    H., W. J. P., L., B. R., Melanie, D., F., V. G. L., Kristian, K., Katerina, K., Ildiko, L., M., M. B., Kalayci, O. T., Julio, R., A., W. T., Sean, W., Koutaro, Y., F., K. R. 2022. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism.